首页> 美国卫生研究院文献>Infection and Drug Resistance >Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi-center study

【2h】

Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi-center study

机译：多中心研究表明埃及患者对sofosbuvir / daclatasvir疗法获得持续病毒学应答的隐匿性丙型肝炎病毒感染的患病率和预测因素

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundOccult hepatitis C virus (HCV) infection (OCI) is characterized by the detection of HCV-RNA in non-serum reservoirs, such as peripheral blood mononuclear cells (PBMCs) and/or hepatocytes with undetectable HCV-RNA or antibodies in the serum. In this study, we tried to evaluate the prevalence and possible predictors of OCI in patients who achieved sustained virologic response (SVR) post sofosbuvir/daclatasvir (SOF/DCV) therapy.

机译：背景隐匿性丙型肝炎病毒（HCV）感染（OCI）的特征是在非血清储库中检测到HCV-RNA，例如外周血单核细胞（PBMC）和/或肝细胞中检测不到HCV-RNA或血清中的抗体。在这项研究中，我们试图评估在sofosbuvir / daclatasvir（SOF / DCV）治疗后获得持续病毒学应答（SVR）的患者中OCI的患病率和可能的预测指标。

著录项

期刊名称 Infection and Drug Resistance
作者
Mohamed A Mekky; Hani I Sayed; Mohamed O Abdelmalek; Medhat A Saleh; Osman A Osman; Heba A Osman; Khairy H Morsy; Helal F Hetta;
展开▼
作者单位

展开▼
年(卷),期 2019(12),-1
年度 2019
页码 273–279
总页数 7
原文格式 PDF
正文语种
中图分类药学;
关键词
Occult hepatitis C Direct acting Sofosbuvir;

机译：隐匿性;丙型肝炎;直接作用;索非布韦;

相似文献

外文文献
中文文献
专利

1. Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease [J] . Mandorfer Mattias, Schwabl Philipp, Steiner Sebastian, AIDS . 2016,第7期

机译：索非布韦/达卡他韦的无干扰素治疗可在100％感染HIV /丙型肝炎病毒的晚期肝病患者中实现持续的病毒学应答
2. Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection [J] . Ossama A Ahmed, Mohamed A Elsebaey, Mohamed Hassan A Fouad, Infection and Drug Resistance . 2018,第1期

机译：埃及索非布韦联合达卡他韦联合利巴韦林或不联合利巴韦林治疗的结果和预测因素-感染基因型4 C型肝炎病毒的患者
3. Detection of Occult Hepatitis C Virus Infection in Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents for Recurrent Infection After Liver Transplantation [J] . Elmasry Sandra, Wadhwa Sanya, Bang Bo-Ram, Gastroenterology . 2017,第3期

机译：检测肝脏移植后患者持续发生抗病毒剂的持续病毒性反应的患者患者患者
4. Patients with HCV/HIV Co-infection Achieving a Sustained Virological Response Following HCV Treatment with Peginterferon alfa-2a (PEGASYS) plus Ribavirin (COPEGUS) have Improved Health Related Quality of Life [C] . D.T. Dieterich, M. Rodriguez Torres, J.K. Rockstroh International AIDS Conference . 2004

机译：HCV / HIV的患者在用Peginterferon Alfa-2a（Pegasys）加上利巴韦林（Copegegs）后HCV治疗后实现持续的病毒学反应，具有改善的健康相关的生活质量
5. Patient Experience on Therapy for Hepatitis C Virus, The Impact of Successful Treatment on Liver Stiffness, and The Meaning of Sustained Virologic Response [D] . Nickerson, Jillian Elizabeth 2015

机译：乙型肝炎病毒治疗患者体验，成功治疗对肝硬化的影响，以及持续的病毒性反应的含义
6. Original article: Daclatasvir plus sofosbuvir with or without ribavirin achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort [O] . Tania M Welzel, Jörg Petersen, Kerstin Herzer, -1

机译：原始文章：达卡他韦加索非布韦有或没有利巴韦林在现实世界中的HCV感染和晚期肝病患者中均获得了较高的持续病毒学应答率
7. Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection [O] . Ossama A. Ahmed, Mohamed A Elsebaey, Mohamed Hassan Ahmed Fouad, 2018

机译：与埃及患者基因型4丙型肝炎病毒感染的埃及患者有或没有利巴韦林治疗反应的结果和预测因子。

Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi-center study

摘要

著录项

相似文献

相关主题

期刊订阅